Login to Your Account



Havan'a Go with 'Safer' EGFR

Finding Nimo's Path Forward: Cuban Bid by YM Biosciences

By Randy Osborne


Monday, August 17, 2009
"This has got nothing to do with politics," David Allan, president and CEO of YM Biosciences Inc., likes to say about his firm's effort to win U.S. acceptance for a potential cancer blockbuster that originated in Cuba. "It's got everything to do with medicine, and getting a safe and benign drug to patients."

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription